Literature DB >> 21297325

A rare case of ACTH-independent macronodular adrenal hyperplasia associated with aldosterone-producing adenoma.

Eri Hayakawa1, Takanobu Yoshimoto, Kiichiro Hiraishi, Masako Kato, Hajime Izumiyama, Hironobu Sasano, Yukio Hirata.   

Abstract

A 52-year-old man was evaluated for incidentally discovered bilateral adrenal masses. He had drug-resistant hypertension but lacked Cushingoid features. Endocrinological tests revealed autonomous secretion of cortisol and aldosterone with suppressed plasma ACTH and renin activity. A selective adrenal venous sampling demonstrated aldosterone hypersecretion from the left adrenal vein. The clinical diagnosis of subclinical Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia (AIMAH) associated with primary aldosteronism was made, and he underwent left adrenalectomy; the resected adrenal lesion was consistent with the pathological diagnosis of AIMAH coexistent with aldosterone-producing adenoma (APA). This is a very rare case of AIMAH with concomitant unilateral APA, whose hypertension improved after surgery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21297325     DOI: 10.2169/internalmedicine.50.4351

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  Benign adrenal adenomas secreting excess mineralocorticoids and glucocorticoids.

Authors:  Vivienne Yoon; Aliya Heyliger; Takashi Maekawa; Hironobu Sasano; Kelley Carrick; Stacey Woodruff; Jennifer Rabaglia; Richard J Auchus; Hans K Ghayee
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-09-23

2.  A case of Adrenocoricotrophic hormone -independent bilateral adrenocortical macronodular hyperplasia concomitant with primary aldosteronism.

Authors:  Mao Tokumoto; Naoyoshi Onoda; Yukie Tauchi; Shinichiro Kashiwagi; Satoru Noda; Norikazu Toi; Masahumi Kurajoh; Masahiko Ohsawa; Yuto Yamazaki; Hironobu Sasano; Kosei Hirakawa; Masaichi Ohira
Journal:  BMC Surg       Date:  2017-09-06       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.